<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29206810</article-id>
<article-id pub-id-type="pmc">5916364</article-id>
<article-id pub-id-type="pii">npp2017295</article-id>
<article-id pub-id-type="doi">10.1038/npp.2017.295</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex</article-title>
<alt-title alt-title-type="running">mGluR5 modulation in tuberous sclerosis complex</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kelly</surname>
<given-names>Elyza</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="note1">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaeffer</surname>
<given-names>Samantha M</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="note1">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dhamne</surname>
<given-names>Sameer C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipton</surname>
<given-names>Jonathan O</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindemann</surname>
<given-names>Lothar</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Honer</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaeschke</surname>
<given-names>Georg</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Super</surname>
<given-names>Chloe E</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lammers</surname>
<given-names>Stephen HT</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Modi</surname>
<given-names>Meera E</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silverman</surname>
<given-names>Jill L</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dreier</surname>
<given-names>John R</given-names>
</name>
<xref ref-type="aff" rid="aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwiatkowski</surname>
<given-names>David J</given-names>
</name>
<xref ref-type="aff" rid="aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rotenberg</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7044-2953</contrib-id>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Neurology, Boston Children’s Hospital, F.M. Kirby Neurobiology Center, Harvard Medical School</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Neuroscience, University of Texas Southwestern Medical Center at Dallas</institution>, Dallas, TX, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>Division of Sleep Medicine, Harvard Medical School</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff4"><label>4</label><institution>Roche Pharma Research and Early Development, Discovery Neuroscience, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel</institution>, Basel, <country>Switzerland</country></aff>
<aff id="aff5"><label>5</label><institution>Roche Pharmaceuticals Research and Early Development, Translational Medicine &amp; Biomarkers, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel</institution>, Basel, <country>Switzerland</country></aff>
<aff id="aff6"><label>6</label><institution>Roche Pharmaceuticals Research and Early Development, Therapeutic Modalities, Small Molecule Research, Roche Innovation Center Basel</institution>, Basel, <country>Switzerland</country></aff>
<aff id="aff7"><label>7</label><institution>Department of Psychiatry and Behavioral Sciences, MIND Institute, University of California Davis School of Medicine</institution>, Sacramento, CA, <country>USA</country></aff>
<aff id="aff8"><label>8</label><institution>Department of Medicine, Brigham and Women’s Hospital</institution>, Boston, Massachusetts, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Neurology, Boston Children’s Hospital, F.M. Kirby Neurobiology Center, Harvard Medical School</institution>, 300 Longwood Avenue, Boston, MA 02115, <country>USA</country>, Tel: +617-919-6258, E-mail: <email>mustafa.sahin@childrens.harvard.edu</email></corresp>
<fn fn-type="equal" id="note1">
<label>9</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>05</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>01</month>
<year>2018</year>
</pub-date>
<volume>43</volume>
<issue>6</issue>
<fpage>1457</fpage>
<lpage>1465</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>08</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of <italic>Tsc2</italic> that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the <italic>in vivo</italic> characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated <italic>de novo</italic> synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>